Tenecteplase clinical trials
Also written TNK-tPA, rhTNK-tPA and Metalyse.
How each study uses Tenecteplase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Tenecteplase studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Jun 2000 · TNKASE · BLA 103909 (FDA, Drugs@FDA)
- European Union
- 23 Feb 2001 · Metalyse · EMEA/H/C/000306 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
94 studies that test it; most in 2026 (13); 2 more planned to start later
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 11 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 81
Beijing Tiantan Hospital (12) · General Hospital of Shenyang Military Region (7) · Boehringer Ingelheim (7) · Genentech, Inc. (5) · The First Affiliated Hospital of University of Science and Technology of China (4) · Xuanwu Hospital, Beijing (4) · University of Calgary (4) · Xinqiao Hospital of Chongqing (2)
Often tested with
Tested in the same studies.
Tissue Plasminogen Activator (7) · Minimally Invasive Surgery (1) · Clopidogrel (1) · NONO-42 (1) · Reteplase (1) · Enoxaparin (1)
Related medicines
As reviewed, each with the page that says it.
- A recombinant medicine of Tissue Plasminogen Activator source
- One of Thrombolytics source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 7 in phase 3
Studies that test Tenecteplase, phase 3 first.
- Dec 2026Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion StrokePhase 3 · Xuanwu Hospital, Beijing
- Feb 2027Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYONDPhase 3 · Beijing Tiantan Hospital
- Mar 2027Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic StrokePhase 3 · Beijing Tiantan Hospital
- Aug 2027Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST TrialPhase 3 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Sep 2027Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.Phase 3 · CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
- Oct 2027A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellPhase 3 · Boehringer Ingelheim
- Oct 2027Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time WindowPhase 3 · Xinqiao Hospital of Chongqing
Studies
Open first, then newest update. How each study uses Tenecteplase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 96
- Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 HoursNot yet recruitingPhase 3The First Affiliated Hospital of University of Science and Technology of ChinaNCT07931807Written as Tenecteplase
- ACT-GLOBAL Adaptive Platform Trial for StrokeRecruitingPhase 3The George InstituteNCT06352632Written as Standard-dose intravenous tenecteplase
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellRecruitingPhase 3Boehringer IngelheimNCT07361302Written as Tenecteplase
- Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR MismatchRecruitingPhase 3The First Affiliated Hospital of Zhengzhou UniversityNCT07540416Written as TNK-tPA
- Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 HoursNot yet recruitingPhase 3Fujian Medical University Union HospitalNCT07912970Written as Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
- Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsRecruitingPhase 3Yongjun WangNCT07748039Written as rhTNK-tPA (0.25mg/kg)
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632RecruitingPhase 3University of CalgaryNCT06320431Written as Tenecteplase
- Unknown Time of Onset Stroke RePerfusIon Without Advanced ImagingRecruitingPhase 3First Affiliated Hospital of Guangxi Medical UniversityNCT07475949Written as Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)RecruitingPhase 4General Hospital of Shenyang Military RegionNCT06010628Written as Tenecteplase
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 HoursRecruitingPhase 3Xuanwu Hospital, BeijingNCT07253181Written as Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time WindowRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07606807Written as Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
- Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral AnticoagulantNot yet recruitingPhase 3Hackensack Meridian HealthNCT07621796Written as Intravenous tenecteplase (TNK)
- Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation StrokeRecruitingPhase 2/3University of MelbourneNCT05105633Written as Tenecteplase
- Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)Not yet recruitingPhase 1Gaurav Gupta, MDNCT06696131Written as TNK
- Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion StrokeRecruitingPhase 3Xuanwu Hospital, BeijingNCT06658197Written as Tenecteplase
- Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYONDRecruitingPhase 3Beijing Tiantan HospitalNCT06954155Written as Tenecteplase (0.25mg/kg)
- Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)RecruitingPhase 2General Hospital of Shenyang Military RegionNCT07375966Written as Tenecteplase
- Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)RecruitingPhase 2General Hospital of Shenyang Military RegionNCT07375953Written as Tenecteplase
- Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic StrokeRecruitingPhase 3Beijing Tiantan HospitalNCT07047014Written as Tenecteplase (0.25mg/kg)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 HoursRecruitingPhase 4Xuanwu Hospital, BeijingNCT07203625Written as Tenecteplase thrombolysis
See all 96 studies that test Tenecteplase →
As the comparator · 1 — what is tested is compared with Tenecteplase
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting2
- Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR MismatchNov 9, 2026NCT07540416
- Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsOct 22, 2026NCT07748039
Newly registered3
- Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine HemorrhageNov 16, 2026NCT07939854
- Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 HoursNov 12, 2026NCT07931807
- Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 HoursNov 3, 2026NCT07912970
Codes
What other systems call Tenecteplase · ClinicalTrials.gg INT006808
- MeSH (NLM) D000077785TenecteplaseConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WGD229O42WTENECTEPLASEConfirmed FDA, NLM, Wikidata
- RxNorm 259280Confirmed FDA, Wikidata
- Wikidata Q1644947tenecteplaseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29489TenecteplaseOne source FDA
- DrugBank DB00031One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077785 | Tenecteplase | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WGD229O42W | TENECTEPLASE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 259280 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1644947 | tenecteplase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29489 | Tenecteplase | One source FDA |
| DrugBank | DB00031 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.